Srpski arhiv za celokupno lekarstvo 2010 Volume 138, Issue suppl. 1, Pages: 74-78
https://doi.org/10.2298/SARH10S1074M
Full text ( 419 KB)
Cited by
Thrombin activatable fibrinolysis inhibitor (TAFI): A molecular link between coagulation and fibrinolysis
Miljić Predrag (Clinical Centre of Serbia, Institute of Haematology, Belgrade + School of Medicine, Belgrade)
Heylen Evelien (University of Antwerp, Laboratory of Medical Biochemistry, Antwerp, Belgium)
Willemse Johan (University of Antwerp, Laboratory of Medical Biochemistry, Antwerp, Belgium)
Đorđević Valentina (Institute of Molecular Genetics and Genetic Engineering, Belgrade)
Radojković Dragica (Institute of Molecular Genetics and Genetic Engineering, Belgrade)
Čolović Milica (Clinical Centre of Serbia, Institute of Haematology, Belgrade + School of Medicine, Belgrade)
Elezović Ivo (Clinical Centre of Serbia, Institute of Haematology, Belgrade + School of Medicine, Belgrade)
Hendriks Dirk (University of Antwerp, Laboratory of Medical Biochemistry, Antwerp, Belgium)
Although the maintenance of precise balance between coagulation and
fibrinolysis is of utmost importance for normal haemostasis, until recently
these two systems were considered as completely separate mechanisms involved
in the process of formation and dissolution of blood clot. Thrombin
activatable fibrinolysis inhibitor (TAFI) is a recently described attenuator
of the fibrinolytic rate and is considered to be the molecular link between
coagulation and fibrinolysis. TAFI circulates in plasma as an inactive
precursor and its conversion in active enzyme (TAFIa) occurs by the action of
thrombin or plasmin, but most efficiently by thrombin in the presence of its
cofactor thrombomodulin. Once generated, TAFI down-regulates fibrinolysis by
removing C-terminal lysine residues from partially degraded fibrin; thereby
preventing the upregulation of plasminogen binding and activation. Because
TAFI is activated by thrombin on one side, and acts as the attenuator of
fibrinolysis on another side, it enables fine synchronization between these
two systems. The antifibrinolytic function of TAFI mostly depends on TAFI
concentration, the rate of its activation and the half-life of TAFIa in
plasma. Changes in thrombin generation can have a profound effect on the rate
of TAFI activation, and consequently on the rate of fibrinolysis. Therefore,
it has been hypothesized that increased thrombin generation seen in
thrombophilia patients may enhance TAFI activation, leading to a
hypofibrinolytic state, which may further contribute to the thrombotic
tendency. However, the results of several studies, in which relation between
TAFI level and the occurrence of thromboembolic complications in carriers of
hereditary thrombophilia have been investigated, were not consistent.
Keywords: TAFI, fibrinolysis, hereditary thrombophilia